Malignancy diseases and kidneys: A nephrologist prospect and updated review
Authors:
- Elmukhtar HabasEHElmukhtar Habas
- Raza Mrcp AkbarRARaza Mrcp Akbar
- Nada MBChB ArrayesNANada MBChB Arrayes
- Amnna Mbbch RayaniARAmnna Mbbch Rayani
- Gamal Mrcp AlfitoriGAGamal Mrcp Alfitori
- Eshrak Mbbch HabasEHEshrak Mbbch Habas
- Yaqeen Student MagassabiYMYaqeen Student Magassabi
- Hafidh Msc GhazouaniHGHafidh Msc Ghazouani
- Aisha AladabAAAisha Aladab
- Abdel-Naser MBChB ElzoukiAEAbdel-Naser MBChB Elzouki
Open Access
- 14 April 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (15) , e33505
Abstract
Acute kidney injury (AKI), chronic renal failure, and tubular abnormalities represent the kidney disease spectrum of malignancy. Prompt diagnosis and treatment may prevent or reverse these complications. The pathogenesis of AKI in cancer is multifactorial. AKI affects outcomes in cancer, oncological therapy withdrawal, increased hospitalization rate, and hospital stay. Renal function derangement can be recovered with early detection and targeted therapy of cancers. Identifying patients at higher risk of renal damage and implementing preventive measures without sacrificing the benefits of oncological therapy improve survival. Multidisciplinary approaches, such as relieving obstruction, hydration, etc., are required to minimize the kidney injury rate. Different keywords, texts, and phrases were used to search Google, EMBASE, PubMed, Scopus, and Google Scholar for related original and review articles that serve the article’s aim well. In this nonsystematic article, we aimed to review the published data on cancer-associated kidney complications, their pathogenesis, management, prevention, and the latest updates. Kidney involvement in cancer occurs due to tumor therapy, direct kidney invasion by tumor, or tumor complications. Early diagnosis and therapy improve the survival rate. Pathogenesis of cancer-related kidney involvement is different and complicated. Clinicians’ awareness of all the potential causes of cancer-related complications is essential, and a kidney biopsy should be conducted to confirm the kidney pathologies. Chronic kidney disease is a known complication in malignancy and therapies. Hence, avoiding nephrotoxic drugs, dose standardization, and early cancer detection are mandatory measures to prevent renal involvement.Keywords
This publication has 152 references indexed in Scilit:
- Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and SurvivalPLOS ONE, 2013
- Cancer risk among elderly persons with end-stage renal disease: a population-based case–control studyBMC Nephrology, 2012
- Pivotal Role of Apoptosis Signal-Regulating Kinase 1 in Monoclonal Free Light Chain–Mediated ApoptosisThe American Journal of Pathology, 2012
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- Acute Kidney Injury in Hematopoietic Cell TransplantationSeminars in Nephrology, 2010
- Immunoglobulin Light Chains Activate Tubular Epithelial Cells through Redox SignalingJournal of the American Society of Nephrology, 2010
- Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and OutcomeTransplantation and Cellular Therapy, 2010
- Association of CKD and Cancer Risk in Older PeopleJournal of the American Society of Nephrology, 2009
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004
- Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) StudyJournal of Clinical Oncology, 2003